HONG KONG – A new anticorruption law in South Korea, known as the "Kim Young-ran Act," could have a significant and long-term impact on pharmaceutical companies, even if its focus is much wider than any one industry.
HONG KONG – A new anticorruption law in South Korea, known as the “Kim Young-ran Act,” could have a significant and long-term impact on pharmaceutical companies, even if its focus is much wider than any one industry.
HONG KONG – You win some and you lose some. Fresh from losing a licensing deal with German pharmaceutical giant Boehringer Ingelheim GmbH and watching its stock price plummet, South Korea’s Hanmi Pharmaceutical Co. Ltd. inked an exclusive $910 million development and licensing agreement with Genentech Inc., of South San Francisco, for the development and commercialization of its pan-RAF inhibitor, HM95573.
HONG KONG – South Korean biotech firm Genexine Inc. (KOSDAQ:095700) recently released interim results for its second clinical trial of GX-H9, to treat growth hormone (GH) deficiency.
HONG KONG – South Korean biotech firm Genexine Inc. (KOSDAQ: 095700) recently released interim results for its second clinical trial of GX-H9, to treat growth hormone (GH) deficiency.
HONG KONG – Swiss multinational Novartis AG's South Korean unit is facing further scrutiny after being charged with illegal rebates in February. South Korean prosecutors indicted a former chief executive of Novartis South Korea, Moon Hak-Sun, along with five other former and current company managers over allegations that they illegally paid doctors KRW2.6 billion (US$2.3 million) in return for prescribing the company's drugs to patients over the span of five years, from 2011 to January this year. The Seoul Western District Prosecutors' Office said it has indicted 28 other people, including 15 doctors and six publishers of medical journals, amounting to a total of 34 people. The first of what may wind up being several trials is scheduled to start Sept. 22.
